Overview

Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit

Status:
Completed
Trial end date:
2017-05-24
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, safety, and pharmacokinetics of dexmedetomidine given as continuous IV infusion in pediatric subjects [≥ 45 weeks CGA (corrected gestational age) to <17 years old] requiring sedation under intensive care unit
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Collaborator:
Maruishi Pharmaceutical
Treatments:
Dexmedetomidine